Lazar David E. 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Feb 28, 2025
Insider Transaction Report
Form 4
Lazar David E.
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-26+2,650,000→ 2,650,000 total - Exercise/Conversion
Common Stock
2025-02-26+191,978,820→ 194,628,820 total - Exercise/Conversion
Series D Convertible Preferred Stock
2025-02-26−1,745,262→ 354,738 total→ Common Stock (191,978,820 underlying) - Sale
Common Stock
2025-02-26$0.03/sh−194,628,820$5,507,996→ 0 total - Exercise/Conversion
Series C Convertible Preferred Stock
2025-02-26−1,000,000→ 0 total→ Common Stock (2,650,000 underlying)
Footnotes (9)
- [F1]These shares represent the conversion of 1,000,000 shares of the Series C Convertible Preferred Stock (the "Series C Preferred Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") owned by the Reporting Person into shares of the Company's common stock, par value $0.001 per share (the "Common Stock").
- [F2]The shares of Series C Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
- [F3]These shares represent the conversion of 1,745,262 shares of the Company's Series D Convertible Preferred Stock (the "Series D Preferred Stock") owned by the Reporting Person into shares of Common Stock of the Company.
- [F4]The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
- [F5]On February 26, 2025, the Reporting Person sold 194,628,820 shares of Common Stock in a private transaction for total consideration of $5,500,000.
- [F6]The Series C Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date.
- [F7]At a closing on January 6, 2025, the Reporting Person acquired 1,000,000 shares of Series C Preferred Stock from the Company for a total purchase price of $1,000,000. Each share of Series C Preferred Stock is convertible into 2.65 shares of the Company's Common Stock at any time.
- [F8]The Series D Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date.
- [F9]At a closing on February 6, 2025, the Reporting Person acquired 2,100,000 shares of Series D Preferred Stock from the Company for a total purchase price of $2,100,000. Each share of Series D Preferred Stock is convertible into 110 shares of the Company's Common Stock at any time.